{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:43:06Z","timestamp":1790401386682,"version":"4.1.0"},"reference-count":107,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T00:00:00Z","timestamp":1343174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Heat shock protein 90 (Hsp90) is a conserved and constitutively expressed molecular chaperone and it has been shown to stabilize oncoproteins and facilitate cancer development. Hsp90 has been considered as a therapeutic target for cancers and three classes of Hsp90 inhibitors have been developed: (1) benzoquinone ansamycin and its derivatives, (2) radicicol and its derivates, and (3) small synthetic inhibitors. The roles of these inhibitors in cancer treatment have been studied in laboratories and clinical trials, and some encouraging results have been obtained. Interestingly, targeting of Hsp90 has been shown to be effective in inhibition of cancer stem cells responsible for leukemia initiation and progression, providing a strategy for finding a cure. Because cancer stem cells are well defined in some human leukemias, we will focus on hematologic malignancies in this review.<\/jats:p>","DOI":"10.3390\/ph5080779","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T11:40:38Z","timestamp":1343216438000},"page":"779-801","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Heat Shock Protein 90 and Role of Its Chemical Inhibitors in Treatment of Hematologic Malignancies"],"prefix":"10.3390","volume":"5","author":[{"given":"Ngoc","family":"Ho","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoguang","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2012,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrm2918","article-title":"Hsp90 at the hub of protein homeostasis: Emerging mechanistic insights","volume":"11","author":"Taipale","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic Hsp90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","first-page":"355","article-title":"The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome","volume":"11","author":"An","year":"2000","journal-title":"Cell Growth Differ."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.20111694","article-title":"Genetic resistance to JAK2 enzymatic inhibitors is overcome by Hsp90 inhibition","volume":"209","author":"Weigert","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1128\/MCB.00265-08","article-title":"Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias","volume":"28","author":"Kurokawa","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"ref_7","first-page":"517","article-title":"Expression and crystallization of the yeast Hsp82 chaperone, and preliminary X-ray diffraction studies of the amino-terminal domain","volume":"25","author":"Prodromou","year":"1996","journal-title":"Proteins"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cell.2006.09.027","article-title":"Structural analysis of E. Coli Hsp90 reveals dramatic nucleotide-dependent conformational rearrangements","volume":"127","author":"Shiau","year":"2006","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/nature04716","article-title":"Crystal structure of an Hsp90-nucleotide-p23\/Sba1 closed chaperone complex","volume":"440","author":"Ali","year":"2006","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.molcel.2007.08.024","article-title":"Structures of GRP94-nucleotide complexes reveal mechanistic differences between the Hsp90 chaperones","volume":"28","author":"Dollins","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"18473","DOI":"10.1074\/jbc.R800007200","article-title":"The Hsp90 chaperone machinery","volume":"283","author":"Wandinger","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"22559","DOI":"10.1074\/jbc.M109.031658","article-title":"The charged linker region is an important regulator of Hsp90 function","volume":"284","author":"Hainzl","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_13","first-page":"1459","article-title":"The carboxy-terminal region of mammalian Hsp90 is required for its dimerization and function in vivo","volume":"14","author":"Minami","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1097-2765(02)00785-2","article-title":"Activation of the atpase activity of Hsp90 by the stress-regulated cochaperone aha1","volume":"10","author":"Panaretou","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1074\/jbc.M007583200","article-title":"Hsp90 regulates p50(CDC37) function during the biogenesis of the activeconformation of the heme-regulated eIF2 alpha kinase","volume":"276","author":"Shao","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0092-8674(03)01027-4","article-title":"The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37)","volume":"116","author":"Roe","year":"2004","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11010-008-9818-1","article-title":"Evaluating ck2 activity with the antibody specific for the ck2-phosphorylated form of a kinase-targeting cochaperone cdc37","volume":"316","author":"Miyata","year":"2008","journal-title":"Mol. Cell. Biochem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"26235","DOI":"10.1074\/jbc.M605417200","article-title":"Defining the requirements for Hsp40 and Hsp70 in the Hsp90 chaperone pathway","volume":"281","author":"Cintron","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1158\/0008-5472.CAN-08-0644","article-title":"Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion","volume":"68","author":"Yang","year":"2008","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.molcel.2006.12.008","article-title":"An acetylation site in the middle domain of Hsp90 regulates chaperone function","volume":"25","author":"Scroggins","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"Hdac6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.1073\/pnas.0407294102","article-title":"S-nitrosylation of Hsp90 promotes the inhibition of its atpase and endothelial nitric oxide synthase regulatory activities","volume":"102","author":"Villanueva","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-04-0006","article-title":"Cotreatment with 17-allylamino-demethoxygeldanamycin and flt-3 kinase inhibitor pkc412 is highly effective against human acute myelogenous leukemia cells with mutant flt-3","volume":"64","author":"George","year":"2004","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1172\/JCI42442","article-title":"Hsp90 is a therapeutic target in jak2-dependent myeloproliferative neoplasms in mice and humans","volume":"120","author":"Marubayashi","year":"2010","journal-title":"J. Clin. Invest."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The BCR-ABL story: Bench to bedside and back","volume":"22","author":"Wong","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the abl tyrosine kinase on the growth of BCR-ABL positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","article-title":"BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90","volume":"100","author":"Gorre","year":"2002","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrc1592","article-title":"Leukaemia stem cells and the evolution of cancer-stem-cell research","volume":"5","author":"Huntly","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.tcb.2005.07.004","article-title":"Cancer stem cells: Lessons from leukemia","volume":"15","author":"Wang","year":"2005","journal-title":"Trends Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of ph+ leukemia in mice","volume":"103","author":"Hu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"Hif1alpha is required for survival maintenance of chronic myeloid leukemia stem cells","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1349-7006.2011.02181.x","article-title":"HIF-1alpha and Hsp90: Target molecules selected from a tumorigenic papillary thyroid carcinoma cell line","volume":"103","author":"Mo","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/1471-2407-11-520","article-title":"Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: Implications for clinical evaluation","volume":"11","author":"Bohonowych","year":"2011","journal-title":"BMC Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2141.2007.06700.x","article-title":"FLT3 inhibition in acute myeloid leukaemia","volume":"138","author":"Knapper","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1179\/102453312X13336169155619","article-title":"Molecular targeted therapy in acute myeloid leukemia","volume":"17","author":"Daver","year":"2012","journal-title":"Hematology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.stem.2011.04.021","article-title":"All hematopoietic cells develop from hematopoietic stem cells through Flk2\/Flt3-positive progenitor cells","volume":"9","author":"Boyer","year":"2011","journal-title":"Cell Stem Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood.V91.6.1947","article-title":"Flt3high and flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct","volume":"91","author":"Gotze","year":"1998","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"14962","DOI":"10.1074\/jbc.273.24.14962","article-title":"The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells","volume":"273","author":"Marchetto","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.leu.2400921","article-title":"FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates","volume":"12","author":"Marchetto","year":"1998","journal-title":"Leukemia"},{"key":"ref_54","first-page":"238","article-title":"Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells","volume":"10","author":"Rosnet","year":"1996","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the united kingdom medical research council aml 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12192-008-0035-3","article-title":"Significance of heat-shock protein (Hsp) 90 expression in acute myeloid leukemia cells","volume":"13","author":"Flandrin","year":"2008","journal-title":"Cell Stress Chaperones"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2174\/156800909789271486","article-title":"Heat shock protein 90\u2014A potential target in the treatment of human acute myelogenous leukemia","volume":"9","author":"Reikvam","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2011.08960.x","article-title":"Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status\u2014Consequences and potentials for pharmacological intervention","volume":"156","author":"Reikvam","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/sj.leu.2402558","article-title":"Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors","volume":"16","author":"Minami","year":"2002","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"30263","DOI":"10.1074\/jbc.M111.232348","article-title":"C-CBL and CBL-B ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated FLT3 kinase with internal tandem duplication through the ubiquitin proteasome pathway","volume":"286","author":"Oshikawa","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_61","first-page":"1549","article-title":"Immunogenic apoptosis in human acute myeloid leukemia (AML): Primary human aml cells expose calreticulin and release heat shock protein (Hsp) 70 and Hsp90 during apoptosis","volume":"25","author":"Fredly","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.leukres.2009.09.014","article-title":"Clinical correlation of circulating heat shock protein 70 in acute leukemia","volume":"34","author":"Yeh","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ajh.23116","article-title":"Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum Hsp70 and Hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment","volume":"87","author":"Fredly","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/modpathol.3800459","article-title":"Expression of heat-shock protein-90 in non-hodgkin\u2019s lymphomas","volume":"18","author":"Valbuena","year":"2005","journal-title":"Mod. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/leu.2008.111","article-title":"Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma","volume":"22","author":"Stuhmer","year":"2008","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2141.2006.06247.x","article-title":"The heat shock protein 90 inhibitor 17-aag induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9","volume":"135","author":"Georgakis","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1084\/jem.20111910","article-title":"Targeting of kras mutant tumors by Hsp90 inhibitors involves degradation of STK33","volume":"209","author":"Azoitei","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-05-2698","article-title":"17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappab pathway","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood-2006-05-024372","article-title":"STAT3 and mapk signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival","volume":"109","author":"Chatterjee","year":"2007","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"Kuppers","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm.2059","article-title":"A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas","volume":"15","author":"Cerchietti","year":"2009","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Woyach, J.A., Johnson, A.J., and Byrd, J.C. (2012). The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood.","DOI":"10.1182\/blood-2012-02-362624"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1182\/blood-2008-02-139139","article-title":"Geldanamycin-induced lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia","volume":"112","author":"Trentin","year":"2008","journal-title":"Blood"},{"key":"ref_79","first-page":"1799","article-title":"Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers BCR-ABL levels and induces apoptosis and differentiation of BCR-ABL-positive human leukemic blasts","volume":"61","author":"Nimmanapalli","year":"2001","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2010.08265.x","article-title":"Tanespimycin monotherapy in relapsed multiple myeloma: Results of a phase 1 dose-escalation study","volume":"150","author":"Richardson","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1158\/1078-0432.CCR-08-1002","article-title":"Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma","volume":"14","author":"Solit","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10637-006-9208-z","article-title":"A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma","volume":"24","author":"Ronnen","year":"2006","journal-title":"Invest. New Drugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1158\/1078-0432.CCR-08-0221","article-title":"A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer","volume":"14","author":"Heath","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3324\/haematol.2011.049551","article-title":"Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia","volume":"96","author":"Kaufmann","year":"2011","journal-title":"Haematologica"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-004-0939-2","article-title":"In vivo antitumor efficacy of 17-dmag (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative","volume":"56","author":"Hollingshead","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1158\/1078-0432.CCR-05-2282","article-title":"Synergistic interactions between dmag and mitogen-activated protein kinase kinase 1\/2 inhibitors in bcr\/abl+ leukemia cells sensitive and resistant to imatinib mesylate","volume":"12","author":"Nguyen","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2010-01-263756","article-title":"17-dmag targets the nuclear factor-kappab family of proteins to induce apoptosis in chronic lymphocytic leukemia: Clinical implications of Hsp90 inhibition","volume":"116","author":"Hertlein","year":"2010","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2011.04.022","article-title":"The anti-proliferative effect of heat shock protein 90 inhibitor, 17-dmag, on non-small-cell lung cancers being resistant to egfr tyrosine kinase inhibitor","volume":"75","author":"Kobayashi","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/leu.2009.292","article-title":"Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia","volume":"24","author":"Lancet","year":"2010","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","article-title":"The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival er chaperone bip\/grp78","volume":"117","author":"Roue","year":"2011","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.2008.07484.x","article-title":"The heat shock protein 90 inhibitor IPI-504 induces apoptosis of akt-dependent diffuse large B-cell lymphomas","volume":"144","author":"Abramson","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1200\/JCO.2010.30.8338","article-title":"Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer","volume":"28","author":"Sequist","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2174\/1568009033481859","article-title":"Development of radicicol analogues","volume":"3","author":"Soga","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood.V96.6.2284","article-title":"Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential g(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of BCR-ABL with Hsp90 complex","volume":"96","author":"Shiotsu","year":"2000","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1021\/jm050759r","article-title":"Heat shock protein 90 inhibitors. A text book example of medicinal chemistry?","volume":"48","author":"Janin","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/1568009033481778","article-title":"Development of purine-scaffold small molecule inhibitors of Hsp90","volume":"3","author":"Chiosis","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1158\/1078-0432.CCR-09-0213","article-title":"Heat shock protein 90 inhibitor BIIB021 (Cnf2024) depletes nf-kappab and sensitizes hodgkin\u2019s lymphoma cells for natural killer cell-mediated cytotoxicity","volume":"15","author":"Boll","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1535-7163.MCT-08-0758","article-title":"BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90","volume":"8","author":"Lundgren","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.coph.2008.06.015","article-title":"Targeting Hsp90: Small-molecule inhibitors and their clinical development","volume":"8","author":"Taldone","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2008-04-151928","article-title":"SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and Erk","volume":"113","author":"Okawa","year":"2009","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/1078-0432.CCR-11-0821","article-title":"A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas","volume":"17","author":"Rajan","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e18552","DOI":"10.1371\/journal.pone.0018552","article-title":"Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK\/STAT signaling","volume":"6","author":"Proia","year":"2011","journal-title":"PLoS One"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.exphem.2008.05.001","article-title":"The novel Hsp90 inhibitor STA-9090 exhibits activity against KIT-dependent and -independent malignant mast cell tumors","volume":"36","author":"Lin","year":"2008","journal-title":"Exp. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/0008-5472.CAN-08-3131","article-title":"Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells","volume":"69","author":"Gaspar","year":"2009","journal-title":"Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"10006","DOI":"10.1158\/0008-5472.CAN-05-2029","article-title":"Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:Quinone oxidoreductase 1: Role of 17-aag hydroquinone in heat shock protein 90 inhibition","volume":"65","author":"Guo","year":"2005","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/cb9000316","article-title":"Structural basis of the radicicol resistance displayed by a fungal Hsp90","volume":"4","author":"Prodromou","year":"2009","journal-title":"ACS Chem. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijbiomac.2009.06.012","article-title":"Expression of Hsp90 chaperone proteins in human tumor tissue","volume":"45","author":"McDowell","year":"2009","journal-title":"Int. J. Biol. Macromol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/5\/8\/779\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:51:27Z","timestamp":1760219487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/5\/8\/779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,25]]},"references-count":107,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2012,8]]}},"alternative-id":["ph5080779"],"URL":"https:\/\/doi.org\/10.3390\/ph5080779","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,25]]}}}